Symbols / MOLN $4.23 -2.54%
MOLN Chart
About
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 158.19M |
| Enterprise Value | 72.95M | Income | -61.65M | Sales | — |
| Book/sh | 2.70 | Cash/sh | 2.49 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -10.66 | PEG | — |
| P/S | — | P/B | 1.57 | P/C | — |
| EV/EBITDA | -1.34 | EV/Sales | — | Quick Ratio | 8.56 |
| Current Ratio | 8.79 | Debt/Eq | 4.54 | LT Debt/Eq | — |
| EPS (ttm) | -2.07 | EPS next Y | -0.40 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-12 | ROA | -26.59% |
| ROE | -55.55% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 37.40M |
| Shs Float | 17.50M | Short Float | 0.09% | Short Ratio | 3.81 |
| Short Interest | — | 52W High | 5.36 | 52W Low | 3.36 |
| Beta | 0.63 | Avg Volume | 4.43K | Volume | 9.11K |
| Target Price | $11.88 | Recom | Strong_buy | Prev Close | $4.34 |
| Price | $4.23 | Change | -2.54% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$11.90
Mean price target
2. Current target
$4.34
Latest analyst target
3. DCF / Fair value
$-13.25
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.34
Low
$3.83
High
$17.11
Mean
$11.90
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-16 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2026-01-27 | init | HC Wainwright & Co. | — → Buy | $13 |
| 2025-12-08 | main | JP Morgan | Neutral → Neutral | $4 |
| 2025-09-03 | main | JP Morgan | Neutral → Neutral | $4 |
| 2025-03-11 | init | LifeSci Capital | — → Outperform | $12 |
| 2023-12-05 | main | JP Morgan | Neutral → Neutral | $5 |
| 2022-08-29 | down | SVB Leerink | Outperform → Market Perform | $8 |
| 2022-05-25 | up | Credit Suisse | Underperform → Neutral | — |
| 2022-04-27 | main | SVB Leerink | — → Outperform | $29 |
| 2022-01-14 | main | SVB Leerink | — → Outperform | $42 |
| 2021-08-27 | main | SVB Leerink | — → Outperform | $35 |
| 2021-07-13 | init | Cowen & Co. | — → Outperform | $50 |
- MOLN Stock: HC Wainwright Reiterates Buy Rating with $13 Target - GuruFocus Mon, 16 Mar 2026 11
- Biotech Molecular Partners banks CHF 93m to fund cancer drug trials to 2028 - Stock Titan hu, 12 Mar 2026 20
- Cowen Maintains Buy on MOLN (Molecular Partners AG) March 16, 2026 - Meyka ue, 17 Mar 2026 05
- Molecular Partners Publishes 2025 Report as Radio-DARPin Pipeline Enters Key Clinical Phase - The Globe and Mail Fri, 13 Mar 2026 21
- Molecular Partners' (MOLN) Buy Rating Reiterated at HC Wainwright - MarketBeat Mon, 16 Mar 2026 12
- TD Cowen reiterates Molecular Partners stock rating on radioligand platform potential - Investing.com Nigeria Mon, 16 Mar 2026 14
- Molecular Partners AG (VTX:MOLN) is definitely on the radar of hedge funds investors who own 50% of the company - Yahoo Finance Mon, 29 Sep 2025 07
- Molecular Partners Posts 2025 Results, Advances Radio-DARPins and Oncology Pipeline - TipRanks Fri, 13 Mar 2026 17
- Molecular Partners (NASDAQ: MOLN) details 2025 loss, cash and trial progress - Stock Titan Fri, 13 Mar 2026 17
- Molecular Partners (NASDAQ:MOLN) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat hu, 12 Mar 2026 22
- MOLN.SW Molecular Partners AG (SIX) CHF 3.75 pre-earnings 11 Mar 2026: key metrics - Meyka Wed, 11 Mar 2026 13
- Molecular Partners: Sluggish Progress But Worth Monitoring (Rating Downgrade) - Seeking Alpha ue, 13 May 2025 07
- Radioactive protein drugs take aim at small cell lung cancer tumors - Stock Titan hu, 26 Feb 2026 08
- MOLN.SW (SIX) Molecular Partners CHF3.94 pre-market Feb 2026: watch March earnings - Meyka Fri, 20 Feb 2026 08
- Targeted radiotherapy MP0712 zeros in on cancer tumors in first patient scans - Stock Titan Mon, 02 Feb 2026 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -654.67K | 325.55K | -985.46K | 139.10K |
| TaxRateForCalcs | 0.09 | 0.09 | 0.19 | 0.19 |
| NormalizedEBITDA | -51.78M | -55.48M | -54.42M | 120.13M |
| TotalUnusualItems | -7.70M | 3.83M | -5.11M | 717.00K |
| TotalUnusualItemsExcludingGoodwill | -7.70M | 3.83M | -5.11M | 717.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -61.65M | -54.04M | -61.98M | 117.85M |
| ReconciledDepreciation | 2.14M | 2.37M | 2.42M | 2.39M |
| EBITDA | -59.49M | -51.65M | -59.53M | 120.85M |
| EBIT | -61.63M | -54.02M | -61.95M | 118.46M |
| NetInterestIncome | 1.49M | 3.35M | 4.23M | 523.00K |
| InterestExpense | 18.00K | 25.00K | 34.00K | 605.00K |
| InterestIncome | 1.52M | 3.38M | 4.28M | 1.14M |
| NormalizedIncome | -54.60M | -57.55M | -57.86M | 117.28M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -61.65M | -54.04M | -61.98M | 117.85M |
| TotalExpenses | 55.44M | 66.19M | 68.15M | 72.94M |
| TotalOperatingIncomeAsReported | -58.12M | -61.22M | -61.11M | 116.61M |
| DilutedAverageShares | 37.27M | 34.03M | 32.77M | 33.27M |
| BasicAverageShares | 37.27M | 34.03M | 32.77M | 32.47M |
| DilutedEPS | -1.65 | -1.59 | -1.89 | 3.54 |
| BasicEPS | -1.65 | -1.59 | -1.89 | 3.63 |
| DilutedNIAvailtoComStockholders | -61.65M | -54.04M | -61.98M | 117.85M |
| NetIncomeCommonStockholders | -61.65M | -54.04M | -61.98M | 117.85M |
| NetIncome | -61.65M | -54.04M | -61.98M | 117.85M |
| NetIncomeIncludingNoncontrollingInterests | -61.65M | -54.04M | -61.98M | 117.85M |
| NetIncomeContinuousOperations | -61.65M | -54.04M | -61.98M | 117.85M |
| TaxProvision | 2.00K | 2.00K | 0.00 | 0.00 |
| PretaxIncome | -61.65M | -54.04M | -61.98M | 117.85M |
| OtherIncomeExpense | -7.70M | 3.83M | -5.11M | 717.00K |
| SpecialIncomeCharges | -2.69M | 0.00 | 0.00 | |
| RestructuringAndMergernAcquisition | 2.69M | 0.00 | 0.00 | |
| GainOnSaleOfSecurity | -5.01M | 3.83M | -5.11M | 717.00K |
| NetNonOperatingInterestIncomeExpense | 1.49M | 3.35M | 4.23M | 523.00K |
| TotalOtherFinanceCost | 15.00K | 13.00K | 15.00K | 14.00K |
| InterestExpenseNonOperating | 18.00K | 25.00K | 34.00K | 605.00K |
| InterestIncomeNonOperating | 1.52M | 3.38M | 4.28M | 1.14M |
| OperatingIncome | -55.44M | -61.22M | -61.11M | 116.61M |
| OperatingExpense | 55.44M | 66.19M | 68.15M | 72.94M |
| OtherOperatingExpenses | -44.00K | -424.00K | ||
| DepreciationAmortizationDepletionIncomeStatement | 371.00K | 419.00K | 367.00K | 416.00K |
| DepreciationAndAmortizationInIncomeStatement | 371.00K | 419.00K | 367.00K | 416.00K |
| ResearchAndDevelopment | 40.19M | 48.60M | 48.78M | 50.75M |
| SellingGeneralAndAdministration | 14.87M | 17.16M | 19.00M | 21.82M |
| GeneralAndAdministrativeExpense | 14.87M | 17.16M | 19.00M | 21.82M |
| OtherGandA | 5.08M | 6.20M | 7.36M | 10.03M |
| SalariesAndWages | 9.79M | 10.96M | 11.64M | 11.79M |
| TotalRevenue | 0.00 | 4.97M | 7.04M | 189.56M |
| OperatingRevenue | 0.00 | 4.97M | 7.04M | 189.56M |
| Line Item | 2024-12-31 | 2023-12-31 | ||
|---|---|---|---|---|
| TreasurySharesNumber | 3.50M | 3.50M | ||
| OrdinarySharesNumber | 37.40M | 36.86M | 32.85M | 36.04M |
| ShareIssued | 37.40M | 40.36M | 36.35M | 36.04M |
| TotalDebt | 3.64M | 2.44M | 3.65M | 4.85M |
| TangibleBookValue | 80.33M | 141.59M | 176.22M | 234.90M |
| InvestedCapital | 80.33M | 141.64M | 176.43M | 235.17M |
| WorkingCapital | 85.85M | 143.50M | 178.04M | 237.50M |
| NetTangibleAssets | 80.33M | 141.59M | 176.22M | 234.90M |
| CapitalLeaseObligations | 3.64M | 2.44M | 3.65M | 4.85M |
| CommonStockEquity | 80.33M | 141.64M | 176.43M | 235.17M |
| TotalCapitalization | 80.33M | 141.64M | 176.43M | 235.17M |
| TotalEquityGrossMinorityInterest | 80.33M | 141.64M | 176.43M | 235.17M |
| StockholdersEquity | 80.33M | 141.64M | 176.43M | 235.17M |
| GainsLossesNotAffectingRetainedEarnings | -981.00K | 0.00 | ||
| OtherEquityAdjustments | -981.00K | |||
| TreasuryStock | 1.13M | 981.00K | 981.00K | 981.00K |
| RetainedEarnings | -311.75M | -246.29M | -191.75M | -127.78M |
| AdditionalPaidInCapital | 389.18M | 384.88M | 365.53M | 360.32M |
| CapitalStock | 4.04M | 4.04M | 3.63M | 3.60M |
| CommonStock | 4.04M | 4.04M | 3.63M | 3.60M |
| TotalLiabilitiesNetMinorityInterest | 21.77M | 16.89M | 21.92M | 27.09M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 10.75M | 6.11M | 7.51M | 9.84M |
| OtherNonCurrentLiabilities | 1.00K | |||
| EmployeeBenefits | 8.15M | 4.88M | 5.06M | 2.55M |
| TradeandOtherPayablesNonCurrent | 160.00K | 0.00 | ||
| NonCurrentDeferredLiabilities | 0.00 | 3.64M | 6.92M | |
| NonCurrentDeferredRevenue | 0.00 | 3.64M | 6.92M | |
| LongTermDebtAndCapitalLeaseObligation | 2.44M | 1.23M | 2.44M | 3.65M |
| LongTermCapitalLeaseObligation | 2.44M | 1.23M | 2.44M | 3.65M |
| CurrentLiabilities | 11.03M | 10.79M | 14.42M | 17.25M |
| OtherCurrentLiabilities | 1.00K | |||
| CurrentDeferredLiabilities | 0.00 | 4.33M | 6.41M | 28.31M |
| CurrentDeferredRevenue | 0.00 | 4.33M | 6.41M | 28.31M |
| CurrentDebtAndCapitalLeaseObligation | 1.21M | 1.22M | 1.21M | 1.20M |
| CurrentCapitalLeaseObligation | 1.21M | 1.22M | 1.21M | 1.20M |
| PayablesAndAccruedExpenses | 9.82M | 9.57M | 8.88M | 9.64M |
| CurrentAccruedExpenses | 8.05M | 7.71M | 7.55M | 7.50M |
| Payables | 1.77M | 1.86M | 1.33M | 2.14M |
| OtherPayable | 829.00K | 1.18M | 918.00K | 1.15M |
| TotalTaxPayable | 0.00 | 855.00K | ||
| AccountsPayable | 937.00K | 679.00K | 410.00K | 997.00K |
| TotalAssets | 102.11M | 158.53M | 198.35M | 262.26M |
| TotalNonCurrentAssets | 5.23M | 4.25M | 5.89M | 7.51M |
| OtherNonCurrentAssets | 1.00K | |||
| GoodwillAndOtherIntangibleAssets | 2.00K | 49.00K | 212.00K | 271.00K |
| OtherIntangibleAssets | 2.00K | 49.00K | 212.00K | 271.00K |
| NetPPE | 5.23M | 4.20M | 5.68M | 7.24M |
| AccumulatedDepreciation | -19.87M | -18.27M | -16.34M | -14.70M |
| GrossPPE | 25.10M | 22.46M | 22.02M | 21.93M |
| Leases | 633.00K | 633.00K | 633.00K | 624.00K |
| OtherProperties | 22.63M | 19.62M | 19.36M | 9.65M |
| MachineryFurnitureEquipment | 1.84M | 2.21M | 2.03M | 11.66M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 96.88M | 154.28M | 192.46M | 254.75M |
| OtherCurrentAssets | -1.00K | |||
| PrepaidAssets | 1.91M | 2.25M | 2.49M | 3.91M |
| Receivables | 1.91M | 2.59M | 3.08M | 1.70M |
| OtherReceivables | 152.00K | 353.00K | 1.20M | 754.00K |
| TaxesReceivable | 1.50M | 1.95M | 1.59M | 423.00K |
| AccountsReceivable | 253.00K | 286.00K | 295.00K | 521.00K |
| CashCashEquivalentsAndShortTermInvestments | 93.06M | 149.44M | 186.89M | 249.14M |
| OtherShortTermInvestments | 10.40M | 85.56M | 119.58M | 161.20M |
| CashAndCashEquivalents | 82.65M | 63.87M | 67.31M | 87.95M |
| CashFinancial | 82.65M | 63.87M | 67.31M | 87.95M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -51.97M | -59.97M | -59.81M | 117.15M |
| RepurchaseOfCapitalStock | 0.00 | 0.00 | -631.00K | 0.00 |
| RepaymentOfDebt | -1.21M | -1.21M | -1.20M | -1.19M |
| IssuanceOfCapitalStock | 0.00 | 17.34M | 0.00 | 0.00 |
| CapitalExpenditure | -714.00K | -723.00K | -808.00K | -1.42M |
| EndCashPosition | 82.65M | 63.87M | 67.31M | 87.95M |
| BeginningCashPosition | 63.87M | 67.31M | 87.95M | 71.81M |
| EffectOfExchangeRateChanges | -1.36M | 894.00K | -5.10M | 258.00K |
| ChangesInCash | 20.14M | -4.33M | -15.54M | 15.88M |
| FinancingCashFlow | -1.15M | 14.43M | -1.17M | -1.57M |
| CashFlowFromContinuingFinancingActivities | -1.15M | 14.43M | -1.17M | -1.57M |
| NetOtherFinancingCharges | -1.74M | |||
| ProceedsFromStockOptionExercised | 63.00K | 40.00K | 31.00K | 250.00K |
| NetCommonStockIssuance | 0.00 | 17.34M | 0.00 | -631.00K |
| CommonStockPayments | 0.00 | 0.00 | -631.00K | 0.00 |
| CommonStockIssuance | 0.00 | 17.34M | 0.00 | 0.00 |
| NetIssuancePaymentsOfDebt | -1.21M | -1.21M | -1.20M | -1.19M |
| NetLongTermDebtIssuance | -1.21M | -1.21M | -1.20M | -1.19M |
| LongTermDebtPayments | -1.21M | -1.21M | -1.20M | -1.19M |
| InvestingCashFlow | 72.55M | 40.49M | 44.64M | -101.12M |
| CashFlowFromContinuingInvestingActivities | 72.55M | 40.49M | 44.64M | -101.12M |
| InterestReceivedCFI | 1.73M | 4.24M | 3.83M | 494.00K |
| NetInvestmentPurchaseAndSale | 71.54M | 36.97M | 41.62M | -100.20M |
| SaleOfInvestment | 137.81M | 277.01M | 319.44M | 199.22M |
| PurchaseOfInvestment | -66.28M | -240.04M | -277.82M | -299.42M |
| NetIntangiblesPurchaseAndSale | 0.00 | -18.00K | -233.00K | -240.00K |
| PurchaseOfIntangibles | 0.00 | -18.00K | -233.00K | -240.00K |
| NetPPEPurchaseAndSale | -714.00K | -705.00K | -575.00K | -1.18M |
| PurchaseOfPPE | -714.00K | -705.00K | -575.00K | -1.18M |
| OperatingCashFlow | -51.26M | -59.25M | -59.01M | 118.57M |
| CashFlowFromContinuingOperatingActivities | -51.26M | -59.25M | -59.01M | 118.57M |
| TaxesRefundPaid | 0.00 | 0.00 | 0.00 | 0.00 |
| InterestPaidCFO | -18.00K | -26.00K | -34.00K | -646.00K |
| ChangeInWorkingCapital | 1.21M | -3.80M | -6.01M | -6.01M |
| ChangeInOtherWorkingCapital | -18.00K | -4.37M | -5.73M | -25.29M |
| ChangeInOtherCurrentAssets | 335.00K | 237.00K | 1.42M | 1.79M |
| ChangeInPayablesAndAccruedExpense | 408.00K | 685.00K | -767.00K | -7.77M |
| ChangeInAccruedExpense | 343.00K | 161.00K | 45.00K | -2.43M |
| ChangeInPayable | 65.00K | 524.00K | -812.00K | -5.34M |
| ChangeInAccountPayable | 524.00K | -812.00K | -5.34M | |
| ChangeInPrepaidAssets | -4.45M | |||
| ChangeInReceivables | 485.00K | -347.00K | -933.00K | 25.26M |
| OtherNonCashItems | 3.18M | -7.19M | 861.00K | -1.25M |
| StockBasedCompensation | 4.42M | 4.11M | 5.21M | 5.09M |
| DeferredTax | 2.00K | 2.00K | 0.00 | 0.00 |
| DeferredIncomeTax | 2.00K | 2.00K | 0.00 | 0.00 |
| DepreciationAmortizationDepletion | 2.14M | 2.37M | 2.42M | 2.39M |
| DepreciationAndAmortization | 2.14M | 2.37M | 2.42M | 2.39M |
| AmortizationCashFlow | 46.00K | 181.00K | 292.00K | |
| AmortizationOfIntangibles | 46.00K | 181.00K | 292.00K | |
| Depreciation | 2.10M | 2.19M | 2.13M | |
| OperatingGainsLosses | -546.00K | -670.00K | 535.00K | 1.15M |
| PensionAndEmployeeBenefitExpense | -546.00K | -670.00K | 535.00K | 1.15M |
| NetIncomeFromContinuingOperations | -61.65M | -54.04M | -61.98M | 117.85M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for MOLN
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|